Medicine and Dentistry
Cystectomy
100%
Bladder Cancer
98%
Prostate Cancer
97%
Polycystic Kidney Disease
85%
Recurrent Disease
62%
Carbon 11
60%
Choline
60%
Kidney Slice
60%
Neoplasm
59%
Transitional Cell Carcinoma
57%
Kidney Fibrosis
57%
Muscle Invasive Bladder Cancer
52%
Positron Emission Tomography
52%
Nephrectomy
52%
Urology
47%
Prostatectomy
42%
External Beam Radiotherapy
42%
Positron Emission Tomography
42%
Bladder
41%
Positron Emission Tomography-Computed Tomography
40%
Quality of Life
40%
Choline C 11
40%
Upper Urinary Tract
35%
Disease Specific Survival
32%
Ex Vivo
32%
Randomized Controlled Trial
31%
Vasculotropin
30%
Metastatic Carcinoma
28%
Lymph Node Metastasis
28%
Time to Treatment
28%
Tolvaptan
28%
Epidermal Growth Factor Receptor
28%
Kidney Metastasis
28%
Medical Oncology
28%
Urologist
26%
Radiation Therapy
25%
Biopsy
25%
Biochemical Recurrence
24%
Prostate Specific Membrane Antigen
21%
Fibrogenesis
21%
Clinical Trial
21%
Fibrosis
20%
Prostate Specific Antigen
19%
Cancer Registry
19%
Disease
18%
Kidney Function
18%
Nerve Block
17%
Clear Cell Renal Cell Carcinoma
17%
Chronic Pain
17%
Cancer Recurrence
17%
Pharmacology, Toxicology and Pharmaceutical Science
Recurrent Disease
70%
Muscle Invasive Bladder Cancer
57%
Kidney Fibrosis
57%
Bladder Cancer
57%
Prostate Cancer
55%
Carbon 11
50%
Choline
50%
Kidney Polycystic Disease
42%
Choline C 11
40%
Disease Specific Survival
35%
Fibrosis
34%
Neoplasm
31%
Cancer Registry
28%
Castration Resistant Prostate Cancer
28%
Tolvaptan
28%
Enzalutamide
26%
Biochemical Recurrence
25%
Comorbidity
25%
Overall Survival
23%
Disease
23%
Cancer Recurrence
20%
Randomized Controlled Trial
18%
Malignant Neoplasm
17%
Sepsis
16%
Prostate Specific Antigen
15%
Vasopressin V2 Receptor
15%
Everolimus
14%
Zirconium 89
14%
Chronic Pain
14%
Transitional Cell Carcinoma
14%
Kidney Cyst
14%
Kidney Pain
14%
Cabazitaxel
14%
Disease Free Survival
14%
Nintedanib
14%
Surgical Mortality
14%
Non Muscle Invasive Bladder Cancer
14%
Kidney Metastasis
14%
Abiraterone Acetate
14%
Infection
14%
Polyuria
14%
Tyrosine Kinase Receptor
14%
Bevacizumab
14%
Progression Free Survival
13%
Fibronectin
12%
Kidney Disease
12%
Abiraterone
11%
Mitomycin
11%
Chemotherapy
10%
Acute Kidney Failure
10%
Keyphrases
Renal Fibrosis
42%
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
42%
Radical Cystectomy
34%
Nephrectomy
30%
Precision-cut Kidney Slices
28%
Muscle-invasive Bladder Cancer
28%
Upper Tract Urothelial Carcinoma
28%
11C-choline PET
20%
Quality of Life
19%
Ex Vivo Model
17%
Health-related Quality of Life
17%
Fibrogenesis
16%
Predictive Value
16%
Vascular Endothelial Growth Factor
16%
Native Nephrectomy
15%
Bladder Recurrence
14%
Positron Emission Tomography-computed Tomography (PET-CT)
14%
Receptor Signaling
14%
Randomized Controlled Trial
14%
Time-to-treatment
14%
Choline PET-CT
14%
Disease-specific Survival
14%
Multimodal Prehabilitation
14%
Human Kidney
14%
Kidney Pain
14%
Everolimus
14%
High-risk Non-muscle-invasive Bladder Cancer
14%
High-risk Bladder Cancer
14%
Patient Well-being
14%
Multicenter Randomized Controlled Trial
14%
Lymph Node Metastasis
14%
Penile Squamous Cell Carcinoma
14%
Bladder-sparing
14%
Radical Prostatectomy
14%
Epidermal Growth Factor Receptor
14%
Recurrent Prostate Cancer
14%
Renal Cyst Infection
14%
Bladder Cancer
14%
Pyelography
14%
Urography
14%
Disease-free Survival
14%
89Zr-bevacizumab
14%
Refractory Pain
14%
Whole Pelvic Radiotherapy
14%
Elective Nodal Radiotherapy
14%
Screening Platform
14%
Phase II Clinical Trial
14%
Tolvaptan
14%
Early Indicators
14%
Open Radical Cystectomy
14%
